⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL471883 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL3375238 | 0.71 | — | — | |
| SCHEMBL141291 | 0.71 | — | — | |
| SCHEMBL21951355 | 0.71 | — | — | |
| SCHEMBL21951309 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL240731 | 0.71 | — | — | |
| Water SCHEMBL339023 | 0.71 | — | — | |
| Fluoride Ion SCHEMBL404060 | 0.71 | — | — | |
| Water SCHEMBL1323484 | 0.71 | — | — | |
| SCHEMBL1445932 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935179-A1 | RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS | The Trustees of Columbia University in the City of New York (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3793616-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AAV | Voyager Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3758664-A1 | HANDHELD DEVICE WITH VIBRATIONAL MEMBER FOR TREATMENT OF DISORDERS | Olympic Ophthalmics, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3746870-A2 | ECLIPSE CURSOR FOR VIRTUAL CONTENT IN MIXED REALITY DISPLAYS | Magic Leap, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3621975-A1 | COMPOUNDS FOR THE TREATMENT OF SYSTEMIC INSULIN RESISTANCE DISORDERS AND THE USE THEREOF | Galectin Sciences, LLC (US) | 2020-03-18 | — | — | EP | disclosed |
| WO-2019165433-A1 | HANDHELD DEVICE WITH VIBRATIONAL MEMBER FOR TREATMENT OF DISORDERS | Olympic Ophthalmics, Inc. (US) | 2019-08-29 | — | — | WO | disclosed |
| EP-3403338-A1 | APPARATUS, SYSTEM AND METHOD OF COMMUNICATING A MULTIPLE-INPUT-MULTIPLE-OUTPUT (MIMO) TRANSMISSION | INTEL Corporation (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2018209276-A1 | COMPOUNDS FOR THE TREATMENT OF SYSTEMIC INSULIN RESISTANCE DISORDERS AND THE USE THEREOF | GALECTIN SCIENCES, LLC (US) | 2018-11-15 | — | — | WO | disclosed |
| WO-2018144445-A1 | METHODS FOR TREATING HEMATOLOGICAL CANCER AND THE USE OF BIOMARKERS AS A PREDICTOR FOR RESPONSIVENESS TO TREATMENT COMPOUNDS | CELGENE CORPORATION (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2016205163-A1 | SURGICAL STAPLING INSTRUMENTS WITH LOCKOUT ARRANGEMENTS FOR PREVENTING FIRING SYSTEM ACTUATION WHEN A CARTRIDGE IS SPENT OR MISSING | ETHICON ENDO-SURGERY, LLC (PR) | 2016-12-22 | — | — | WO | disclosed |
| CN-101557726-A | High-potency sweetener composition with Rubisco protein, Rubiscolin, Rubiscolin derivatives, ACE inhibitory peptides, and combinations thereof, and compositions sweetened therewith | COCA COLA CO (US) | 2009-10-14 | — | — | CN | disclosed |
| WO-2009120909-A1 | METHODS AND SYSTEMS FOR ASSESSING CLINICAL OUTCOMES | THERANOS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-2091358-A2 | HIGH-POTENCY SWEETENER COMPOSITION WITH RUBISCO PROTEIN, RUBISCOLIN, RUBISCOLIN DERIVATIVES, ACE INHIBITORY PEPTIDES, AND COMBINATIONS THEREOF, AND COMPOSITIONS SWEETENED THEREWITH | THE COCA-COLA COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2081893-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2009075538-A2 | APPARATUS FOR TRANSMITTING AND RECEIVING A SIGNAL AND METHOD OF TRANSMITTING AND RECEIVING A SIGNAL | LG ELECTRONICS INC. (KR) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009065071-A1 | METHOD AND SYSTEM USING KEYWORD VECTORS AND ASSOCIATED METRICS FOR LEARNING AND PREDICTION OF USER CORRELATION OF TARGETED CONTENT MESSAGES IN A MOBILE ENVIRONMENT | QUALCOMM INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008057964-A2 | HIGH-POTENCY SWEETENER COMPOSITION WITH RUBISCO PROTEIN, RUBISCOLIN, RUBISCOLIN DERIVATIVES, ACE INHIBITORY PEPTIDES, AND COMBINATIONS THEREOF, AND COMPOSITIONS SWEETENED THEREWITH | THE COCA-COLA COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008049116-A2 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1608632-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078733-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-16 | — | — | WO | disclosed |